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Abstract
Background: Associations of serum calcium levels with the metabolic syndrome and other novel cardio-metabolic risk
factors not classically included in the metabolic syndrome, such as those involved in oxidative stress, are largely unexplored.
We analyzed the association of albumin-corrected serum calcium levels with conventional and non-conventional cardio-
metabolic risk factors in a general adult population.
Methodology/Principal Findings: The CoLaus study is a population-based study including Caucasians from Lausanne,
Switzerland. The metabolic syndrome was defined using the Adult Treatment Panel III criteria. Non-conventional cardio-
metabolic risk factors considered included: fat mass, leptin, LDL particle size, apolipoprotein B, fasting insulin, adiponectin,
ultrasensitive CRP, serum uric acid, homocysteine, and gamma-glutamyltransferase. We used adjusted standardized
multivariable regression to compare the association of each cardio-metabolic risk factor with albumin-corrected serum
calcium. We assessed associations of albumin-corrected serum calcium with the cumulative number of non-conventional
cardio-metabolic risk factors. We analyzed 4,231 subjects aged 35 to 75 years. Corrected serum calcium increased with both
the number of the metabolic syndrome components and the number of non-conventional cardio-metabolic risk factors,
independently of the metabolic syndrome and BMI. Among conventional and non-conventional cardio-metabolic risk
factors, the strongest positive associations were found for factors related to oxidative stress (uric acid, homocysteine and
gamma-glutamyltransferase). Adiponectin had the strongest negative association with corrected serum calcium.
Conclusions/Significance: Serum calcium was associated with the metabolic syndrome and with non-conventional cardio-
metabolic risk factors independently of the metabolic syndrome. Associations with uric acid, homocysteine and gamma-
glutamyltransferase were the strongest. These novel findings suggest that serum calcium levels may be associated with
cardiovascular risk via oxidative stress.
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Introduction
Increased serum calcium concentration has been associated
with high blood pressure (BP)[1], impaired glucose tolerance [2],
and dyslipidemia [3,4]. More recently, increased serum calcium
concentration has been described as a feature of the metabolic
syndrome (MSy) [5].
Cardio-metabolic components not classically included in the
MSy have been associated with the risk of cardiovascular disease
and include components related to adiposity[6], blood lipids [7],
and insulin resistance [8]. In addition, factors related to
inflammation and oxidative stress have been recently associated
with the MSy. For example, observations suggest that serum levels
of uric acid, homocysteine or gamma-glutamyltransferase (GGT)
might be linked to the MSy [9–11].
While associations of serum calcium with the conventional
components of the MSy on one hand [5], and of non-conventional
cardio-metabolic (NCCM) risk factors with the MSy on the other
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18865hand have been explored [12–18], the relationship between serum
calcium and NCCM risk factors has not been characterized in the
general population. We analyzed the association of albumin-
corrected serum calcium (Cac) with conventional and a broad
range of NCCM risk factors in the Swiss population-based CoLaus
study.
Methods
Objectives
The objectives were to analyze the association of albumin-
corrected serum calcium (Cac) with conventional and non-
conventional cardio-metabolic (NCCM) risk factors in a general
adult population.
Figure 1. Adjusted standardized associations between metabolic components and albumin-corrected calcium. Only non-conventional
metabolic syndrome components that were associated with albumin-corrected calcium in adjusted quintiles analyses: fat mass, LDL-chol, LDL size,
insulin, adiponectin, uric acid, homocysteine, and GGT). Age, sex, smoking, alcohol, menopausal status, eGFR and thiazide use were used as covariates
in the models. *=P value,0.05 for adjusted conventional cardio-metabolic risk factors. #=P value,0.05 for adjusted non-conventional cardio-
metabolic risk factors (not adjusted for conventional factors). &=P value,0.05 for adjusted non-conventional metabolic syndrome components
(adjusted for conventional components).
doi:10.1371/journal.pone.0018865.g001
Figure 2. Albumin-corrected calcium, by number of metabolic
syndrome components: adjusted for age, sex, smoking,
alcohol, menopause status, eGFR, and thiazide use. P value for
trend ,0.001 for model with and without BMI adjustment.
doi:10.1371/journal.pone.0018865.g002
Figure 3. Albumin-corrected calcium, by number of non-
conventional metabolic syndrome components: adjusted for
age, sex, smoking, alcohol, menopause status, eGFR, thiazide
use, and conventional metabolic syndrome components. P
value for trend,0.001 for model with and without BMI adjustment.
Only non-conventional metabolic syndrome components that were
associated with albumin-corrected calcium in adjusted quintiles
analyses (fat mass, LDL-chol, LDL size, insulin, adiponectin, uric acid,
homocysteine, and GGT) are taken into account.
doi:10.1371/journal.pone.0018865.g003
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The sampling procedure of the CoLaus study has been
described elsewhere [19]. Briefly, a simple, non-stratified random
sample of 35% of the overall population was drawn. The following
inclusion criteria applied: a) written informed consent; b) aged 35–
75 years; c) willingness to take part in the examination and donate
blood sample; d) Caucasian origin.
Assessment process and clinical data
Recruitment began in June 2003 and ended in May 2006. All
participants attended the outpatient clinic of the University
Hospital of Lausanne in the morning after an overnight fast.
Data were collected by trained field interviewers using standard-
ized questionnaires. Body mass index (BMI) was defined as
weight/height
2. Waist and hip circumferences were measured as
recommended [20]. Fat and fat-free masses were assessed by
electrical bioimpedance [21] using the BodystatH 1500 analyzer
(Isle of Man, British Isles). BP was measured thrice on the left arm
after at least 10 minutes rest in the seated position using a clinically
validated automated oscillometric device (OmronH HEM-907,
Matsusaka, Japan) with a standard cuff, or a large cuff if arm
circumference was $33 cm. The average of the last two BP
readings was used for analyses. Hypertension was defined as mean
systolic BP (SBP)$140 mmHg or mean diastolic BP
(DBP)$90 mmHg or presence of anti-hypertensive medication.
For the purpose of the present analysis, smoking was defined as
present if a participant reported to be a current smoker at the time
of examination, regular alcohol consumption was defined as
present for participants reporting to drink alcohol at least once a
day, and post-menopausal status was self-reported. Diabetes was
defined as a fasting glucose$7 mmol/L and/or presence of
antidiabetic drug treatment (insulin or oral drugs).
Biologic data
The complete description of markers and types of assay used for
the purpose of this analysis is reported in Table S1. Total serum
calcium was measured by O-cresolphtalein and albumin by
bromocresol green. Cac was calculated using the following
formula: Cac=Serum total calcium-0.012 (serum albumin/
0.9677239.55). This formula was derived by the central
laboratory of the University Hospital of Lausanne (Centre
Hospitalier Universitaire Vaudois, CHUV) based on data from
320 consecutive outpatients without disorders of phosphocalcic
metabolism. In CoLaus, Cac using this formula presented no
residual correlation with serum albumin. Glomerular filtration rate
was estimated using the abbreviated Modification of the Diet in
Renal Disease (MDRD) formula: 1866(serum creatinine [mmol/
L]/88.4)
(21.154)6age
(20.203)6F, where F=1 for men and F=0.742
for women [22].
Conventional and non-conventional cardio-metabolic
components
The MSy was defined using the Adult Treatment Panel III
criteria [23] as presenting with 3 or more of the following criteria:
(1) waist circumference$102 cm in men and $88 cm in women;
(2) SBP$130 mmHg or DBP$85 mmHg or medication use; (3)
triglycerides$1.69 mmol/L (150 mg/dL); (4) HDL cholester-
ol,1.04 mmol/L (40 mg/dL) in men and,1.30 mmol/L
(50 mg/dL) in women, or medication use; (5) fasting plasma
glucose$6.1 mmol/L (110 mg/dL) or medication use. We did not
consider drug treatment for elevated triglycerides in the definition
of elevated triglycerides. Components of the MSy were defined as
conventional cardio-metabolic risk factors. Cardio-metabolic com-
ponents that are not included in the MSy were defined as
non-conventional cardio-metabolic (NCCM) risk factors and classified
Table 1. Characteristics of the 4,231 individuals from the CoLaus study.
Men (N=1,976) Women (N=2,255)
Mean or % SD Mean or % SD P value
Age (years) 53.5 10.9 53.8 10.8 0.466
Body mass index (kg/m
2) 27.1 3.8 25.2 4.4 ,0.001
Cigarette smoking (%) 27.2 - 23.8 - 0.010
Regular alcohol consumption (%) 35.6 - 15.6 - ,0.001
Post-menopause (%) - - 57.0 -
Fasting blood glucose$7 mmol/L (%) 10.2 - 3.46 - ,0.001
Fasting blood glucose$6.1 mmol/L* (%) 20.7 7.8 ,0.001
SBP$140 and or DBP$90 mmHg (%) 45.6 - 31.4 - ,0.001
SBP$130 and or DBP$80 mmHg (%)* 62.5 - 45.7 - ,0.001
Waist circumference$102 cm in men or$88 cm in women* (%) 27.5 31.6 0.004
HDL-cholesterol,1.04 in men or,1.30 mmol/L in women* (%) 11.3 13.5 0.028
Triglycerides$1.69 mmol/L* (%) 35.2 16.0 ,0.001
ATPIII Metabolic syndrome (%) 22.8 - 13.7 ,0.001
eGFR (ml/min/1.73 m
2) 86.0 16.9 80.6 15.3 ,0.001
Serum calcium (mmol/L) 2.29 0.09 2.29 0.10 0.162
Serum albumin (g/L) 44.6 2.5 43.8 2.4 ,0.001
Albumin-corrected calcium (mmol/L) 2.21 0.08 2.22 0.09 0.017
*criteria used for the ATPIII Metabolic syndrome definition. SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-cholesterol, high-density-lipoprotein
cholesterol; eGFR, GFR estimated using the MDRD formula.
doi:10.1371/journal.pone.0018865.t001
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mL); (ii)Blood lipids: LDL-cholesterol (mmol/L), LDL size (ang-
stro ¨m), apolipoprotein B (mg/dL); (iii)Insulin resistance: fasting
insulin (mU/mL), adiponectin (mg/mL); (iv)Inflammation-oxidative
stress: ultrasensitive CRP (mg/L), serum uric acid (mmol/L),
homocysteine (mmol/L), GGT (UI/L).
Ethics
The CoLaus study complied with the Declaration of Helsinki
and was approved by the local Institutional Ethic Committee
(Baudraz Marcel-Andre ´, Boillat Marcel-Andre ´, Gardaz Jean-
Patrice, Joye Charles, Lejeune Ferdy, Pannatier Andre ´, Reymond
Catherine, Rossel Martine, Burnand Bernard). All participants
gave written informed consent.
Statistical analyses
Statistical analyses were performed using Stata 10.0 (Stata
Corp, College Station, USA). Continuous variables were expressed
as mean 6 standard deviation (s.d.) or as median and interquartile
range [IQR]. Categorical variables were expressed as number of
subjects and percentage.
Linear and median regressions were used to assess the
association of serum Cac with conventional and NCCM risk
factors. Non-normally distributed variables were transformed (log
or cubic transformation). Associations were considered with serum
Cac taken as quintiles (quintiles analysis) and as a continuous
variable (standardized and score analyses).
In quintiles analysis, interaction with gender and trends by
quintiles were assessed using median regression, adjusting for age,
smoking, alcohol consumption, menopausal status, eGFR, and
thiazide use. Robust regression was used whenever models were
unstable. Adjusted standardized multivariable linear regression
was used to compare the association with Cac of each of the
cardio-metabolic risk factors. S.d. equals 1 for all standardized
beta coefficients. Associations of serum Cac with the number of
cardio-metabolic risk factors were then assessed. Each conven-
tional cardio-metabolic risk factor was included in a score using
the ATPIII classification (MSy score; ranged from 0 to 5). For the
NCCM score, subjects in the upper tertile of the risk factor were
assigned a value of 1, whereas subjects in the first and second
tertiles were assigned a value of 0 for each NCCM risk factor
positively correlated with cardiovascular disease, and vice versa for
NCCM risk factor negatively correlated with cardiovascular
disease. Positive and negative correlations were based on the
existing literature. Only NCCM risk factors that showed a
statistically significantly trend with Cac in quintiles analyses were
entered into the NCCM score. The linearity of association
between serum Cac and MSy score, or between serum Cac and
NCCM score, were tested using median regression. When linearity
failed to be rejected, linear trends by score were tested. NCCM
Table 2. Values of conventional and nonconventional parameters involved in the metabolic syndrome in the 4,231 individuals
from the CoLaus study.
Men (N=1,976) Women (N=2,255)
Mean or % SD Mean or % SD P value
Conventional risk factors
SBP (mmHg) 133 17 125 18 ,0.001
DBP (mmHg) 81.8 10.5 77.8 10.6 ,0.001
HDL-cholesterol (mmol/L) 1.41 0.34 1.79 0.42 ,0.001
Triglycerides (mmol/L)* 1.3 0.9–2.0 1.0 0.8–1.4 ,0.001
Fasting blood glucose (mmol/L) 5.83 1.20 5.34 0.89 ,0.001
Waist circumference (cm) 97.4 10.5 83.7 11.6 ,0.001
Adiposity
Fat mass (kg) 20.7 7.3 23.4 8.5 ,0.001
Leptin (ng/mL)* 6.42 4.0–11.1 14.8 8.8–24.0 ,0.001
Blood lipids
LDL-cholesterol (mmol/L) 3.46 0.91 3.30 0.93 ,0.001
LDL size (angstrom)* 272 268–274 274 271–275 ,0.001
Apolipoprotein B (mg/dL)* 152 109–222 135 97–199 ,0.001
Insulin resistance
Fasting insulin (mU/mL)* 8.00 5.8–12.0 6.29 4.6–9.5 ,0.001
Adiponectin (mg/mL)* 6149 4041–9124 10289 6696–15184 ,0.001
Inflammation
CRP (mg/L)* 1.3 0.7–2.6 1.4 0.7–3.0 0.427
Oxidative stress
Serum uric acid (mmol/L) 10.4 8.8–12.7 8.8 7.3–10.7 ,0.001
Homocysteine (mmol/L)* 29.5 21.0–46.5 16.0 12.0–24.0 ,0.001
GGT (UI/L)* 365 76 271 67 ,0.001
See footnote of Table 1. LDL-cholesterol, low-density-lipoprotein cholesterol, GGT, gamma-glutamyltransferase. * Data are median, interquartile range, and 2-sample
Wilcoxon rank-sum test; uCRP=ultrasensitive C reactive protein.
doi:10.1371/journal.pone.0018865.t002
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quintiles. (Men+Women, N=4,231).*
Q1
[2.11 mmol/L]
(N=903)
Q2
[2.17 mmol/L]
(N=800)
Q3
[2.22 mmol/L]
(N=946)
Q4
[2.26 mmol/L]
(N=766)
Q5
[2.33 mmol/L]
(N=816)
P value for
trend
CONVENTIONAL
SBP (mm Hg) 125 127 128 129 130 0.000
[124–126] [126–127] [127–128] [128–130] [129–131]
DBP (mm Hg) 77.5 78.5 79.0 79.8 80.2 0.000
[76.9–78.1] [78.1–78.9] [78.8–79.4] [79.4–80.2] [79.7–80.9]
HDL-cholesterol (mmol/L)** 1.60 1.57 1.59 1.58 1.60 0.32
[1.58–1.62] [1.56–1.58] [1.57–1.59] [1.56–1.59] [1.58–1.62]
Triglycerides (mmol/L) 1.08 1.15 1.17 1.21 1.23 0.000
[1.05–1.12] [1.12–1.17] [1.15–1.19] [1.19–1.24] [1.20–1.27]
Fasting blood glucose
(mmol/L)
5.36 5.40 5.41 5.44 5.44 0.01
[5.32–5.39] [5.38–5.43] [5.39–5.43] [5.41–5.46] [5.40–5.48]
Waist circumference (cm) 87.6 89.1 89.1 89.7 89.3 0.07
[86.8–88.3] [88.6–89.7] [89.7–89.5] [89.1–90.2] [88.5–90.1]
NON CONVENTIONAL
ADIPOSITY
Fat mass (kg) 20.5 20.6 20.9 21.2 21.5 0.001
[20.1–20.9] [20.3–20.9] [20.7–21.2] [20.9–21.5] [21.1–21.9]
Leptin (ng/mL) 11.6 10.9 11.0 10.8 11.0 0.41
[11.2–12.0] [10.7–11.3] [10.8–11.3] [10.5–11.1] [10.6–11.5]
LIPID
LDL-cholesterol(mmol/L) 3.12 3.25 3.33 3.43 3.50 ,0.001
[3.08–3.16] [3.22–3.28] [3.30–3.35] [3.40–3.46] [3.45–3.55]
LDL size (angstro ¨m) 273.0 272.7 272.6 272.5 272.4 0.001
[272.8–273.2] [272.6–272.9] [272.5–272.8] [272.3–272.6] [272.2–272.6]
Apolipoprotein B (mg/dL) 141 143 143 145 144 0.58
[136–146] [140–147] [141–146] [141–148] [139–149]
INSULIN
Fasting insulin (mU/mL) 6.62 7.03 7.27 7.58 7.78 ,0.001
[6.39–6.84] [6.87–7.19] [7.14–7.40] [7.42–7.74] [7.54–8.01]
Adiponectin (mg/mL) 9064 8544 8370 8058 7957 ,0.001
[8739–9389] [8315–8774] [8184–8557] [7823–8293] [7619–8296]
INFLAMMATION
uCRP (mg/L) 1.37 1.38 1.40 1.41 1.42 0.51
[1.27–1.47] [1.31–1.45] [1.34–1.45] [1.34–1.48] [1.32–1.53]
OXIDATIVE STRESS
Serum uric acid (mmol/L) 292 307 311 320 322 ,0.001
[289–296] [305–310] [309–313] [317–322] [318–325]
Homocysteine (mmol/L) 9.12 9.53 9.74 10.03 10.19 ,0.001
[8.99–9.25] [9.44–9.62] [9.66–9.81] [9.93–10.12] [10.05–10.33]
GGT (UI/L) 20.45 22.42 23.23 24.50 25.07 ,0.001
[19.89–21.01] [22.03–22.81] [22.91–23.55] [24.10–24.91] [24.49–25.65]
SBP=systolic blood pressure; DBP=diastolic blood pressure; uCRP=ultrasensitive C reactive protein.
*Results are medians [95% confidence intervals] adjusted for age, smoking, alcohol consumption, menopause status, eGFR, and thiazide use.
**Robust regression was used to model HDL-cholesterol.
doi:10.1371/journal.pone.0018865.t003
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metabolic risk factors. The association analyses between Cac and
the two scores were performed with and without adjustment for
BMI. We only included in the analysis subjects for whom all
variables of interest for the purpose of this study were available.
We conducted sensitivity analyses using an alternative formula to
correct serum calcium for albumin as proposed by Ahlstro ¨m et al,
i.e. calcium+0.019* (42-albumin) [5]. We also performed sensitiv-
ity analyses by including all CoLaus participants in the analyses,
which increases the sample size.
Results
All variables of interest were not available in 1’957 participants,
thus a total of 4,231 subjects were included in the analysis. This
represents 68.4% (4,231/6,188) of the entire CoLaus sample.
Subjects included in the analysis differed from excluded partici-
pants in several aspects (Table S2).
Clinical characteristics by gender are detailed in Table 1. Men
had a higher mean BMI than women, and a higher prevalence of
cigarette smoking, and of regular alcohol consumption, than
women. Men were also more likely to have hypertension and
diabetes than women. Mean serum calcium was similar between
genders whereas Cac was slightly lower in men than in women
(2.2160.08 vs. 2.2260.09 mmol/L).
The distributions of conventional and NCCM risk factors are
presented in Table 2. With the exception of HDL-cholesterol, the
means/medians of all conventional cardio-metabolic risk factors
were higher in men than in women. The MSy was present in 451
men (23%) and 310 women (14%).
As to NCCM risk factors, women had higher median fat mass
and leptin levels than men. LDL-cholesterol and apolipoprotein B
were higher in men than in women, whereas LDL median size was
lower in men. Compared to women, levels of serum uric acid,
homocysteine and GGT were higher in men.
Table 3 shows adjusted associations of conventional and
NCCM risk factors with Cac quintiles. Among the conventional
risk factors, SBP, DBP, triglycerides and fasting blood glucose
were all significantly higher across increasing quintiles of Cac.
Among NCCM risk factors, fat mass increased with increasing
quintiles of Cac (p value=0.001); LDL-cholesterol increased (p
value,0.001) whereas LDL size decreased as Cac quintiles rose (p
value=0.001). Factors related to insulin resistance were signifi-
cantly associated with quintiles of Cac: fasting insulin was
positively and adiponectin negatively associated with Cac quintiles.
Ultrasensitive CRP levels rose with Cac quintiles, thought not
significantly. Among NCCM risk factors related to oxidative stress,
all were increasing with increasing quintiles of Cac (all with
p,0.01). Gender interaction was only statistically significant for
GGT (p,0.001) (sex-specific associations between cardio-meta-
bolic risk factors and Cac quintiles are provided in Tables S3
and S4). Sensitivity analyses including all CoLaus participants led
to similar results, except for a significant association of CRP with
calcium quintiles in men. As CRP was not significantly associated
with calcium quintiles in participants who actually contribute to
the final statistical models, we did not include CRP in the score.
The eight NCCM associated with Cac in the adjusted quintiles
analyses (1) fat mass, (2) LDL-cholesterol, (3) LDL size, (4) insulin,
(5) adiponectin, (6) uric acid, (7) homocysteine, and (8) GGT) were
included in further analyses. The largest pairwise Spearman rank
correlations were between SBP and DBP (0.79), and between fat
mass and waist circumference (0.57).
Figure 1 illustrates adjusted standardized associations between
cardio-metabolic risk factors and Cac taken as the continuous
dependent variable. All conventional cardio-metabolic risk factors
were positively associated with Cac. Triglycerides was the
conventional cardio-metabolic risk factor most strongly associated
with Cac (b=+0.076). NCCM risk factors related to oxidative
stress were the factors most strongly and positively associated with
Cac. Adjusted for age, sex, smoking, alcohol, menopausal status,
eGFR, and thiazide use, standardized beta coefficients for acid
uric, logGGT and logHomocysteine were +0.083, +0.089, and
+0.078, respectively. Adiponectin had the most important negative
association with Cac (b=20.072). Except for fat mass, further
adjustment for conventional cardio-metabolic risk factors did not
meaningfully change the magnitude of the association between
NCCM risk factors and Cac. The standardized beta coefficient of
fat mass increased from 20.002 to 0.071 after further adjustment
for conventional cardio-metabolic risk factors. Further analyses
showed that fat mass was mostly influenced by the introduction of
waist circumference in the model. Standardized beta coefficients
are presented by gender in Table S5.
Respectively 1286 (30.4%), 1278 (30.2%), 924 (21.8%), 526
(12.4%), 187 (4.4%) and 48 (1.1%) subjects had 0, 1, 2, 3, 4, or 5
conventional cardio-metabolic risk factors (MSy score). Figure 2
illustrates the association between MSy score and Cac.C a c
increased with the number of conventional cardio-metabolic risk
factors (p for linear trend,0.001). Further adjustment for BMI did
not change the magnitude or the significance of the association.
Linear trends were significant for men and women considered
separately (Table S6). Sensitivity analyses using the alternate
formula (calcium + 0.019 * [422albumin]) [5] showed higher
corrected calcium levels for each category of MSy or NCCM
components, but similar trends and levels of statistical significance
were observed, which leads the same conclusions (data available
upon request).
Because only 16 (0.37%) subjects presented all 8 NCCM risk
factors, categories 7 and 8 were pooled. Thus, respectively 465
(11.0%), 783 (18.5%), 837 (19.8%), 750 (17.7%), 592 (14.0%),
443 (10.5%), 249 (5.9%), and 112 (2.6%) had 0, 1, 2, 3, 4, 5, 6,
or 7+ NCCM risk factors (NCCM score). The mean number of
NCCM per subjects was 2.7 (SD=1.83). Figure 3 illustrates
the association between NCCM score and Cac. Cac increased
with the number of NCCM risk factors (p for linear
trend,0.001). Further adjustment for BMI did not change the
magnitude and significance of the association. Linear trends
were significant for men and women and considered separately
(Table S7).
Discussion
We found serum calcium to be strongly associated with
conventional MSy components, in particular fasting serum glucose
and serum triglycerides. Serum calcium showed a positive trend
with the number of MSy components, independently of BMI. Cac
increased from 0 to 3 components, followed by a plateau and a
final rise. The association of serum calcium with the number of
MSy components was recently reported in a population-based
study of 1000 elderly subjects [5]. Our study confirmed this
association in a larger population of subjects aged 35–75 years.
Our findings suggest that serum calcium might be considered as an
additional component of the MSy.
In addition, serum calcium was associated with a vast array of
NCCM risk factors, including proxies for insulin resistance and
markers of oxidative stress, independently of the conventional
MSy risk factors. Although the associations with BP [1], insulin
resistance [24] and dyslipidemia [3] have been previously
described, we are not aware that this was reported for serum
Calcium and Novel Cardiometabolic Risk Factors
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population-based sample. The associations of calcium levels and
uric acid have been reported in patients with primary hyperpara-
thyroidism [25,26].
We reported that fasting insulin was significantly associated with
serum calcium, independently of conventional cardio-metabolic
risk factors. Our results were consistent with those of large-scale
studies that found elevated serum calcium levels to be associated
with insulin resistance, measured using fasting insulin or
homeostatic model assessment [2,27,28]. By contrast, serum
calcium has not been shown to be associated with insulin secretion
[24,27]. In our study, the negative association of serum
adiponectin with serum calcium is concordant with the hypothesis
that serum calcium is a marker of insulin resistance because
adiponectin levels are decreased in patients with type 2 diabetes
[29] and in insulin resistance states [30].
Homocysteine, a sulfur-containing amino acid resulting from
the metabolism of methionine and a marker of animal protein
consumption, has been previously associated with the MSy in
some studies [10], but not with the components of the MSy in
healthy men [31]. Homocysteine is an independent risk factor for
cardiovascular disease, most probably through its role on
atherogenesis and oxidative stress [32]. No relationship between
homocysteine and Cac has been described so far, although several
studies pointed out the role of homocysteine and oxidative stress
on bone and thus, the indirect role of homocysteine on calcium
metabolism [33,34].
In humans, uric acid represents the final catabolic pathway for
purines. Uricase activity has been lost over evolution in higher
primates; consequently, humans have high uric acid plasma levels.
This might confer an evolutionary advantage, maybe through its
effect on oxidation. However, the role of uric acid has on oxidative
metabolism is ambiguous. On one hand, it is a powerful anti-
oxidant, representing about half of the anti-oxidant scavenging
capacities of the plasma. On the other hand, its intracellular
metabolism generates superoxide anions and other reactive
oxygen species [35]. A positive association of uric acid and Cac
levels has not been reported before, even though each of them
have been associated with the MSy.[9] A small study has shown a
negative association between calcemia, uric acid levels and
xanthine oxidase activity in 2 healthy volonteers [36]. The
association between Cac and uric acid levels lifts up new
hypothesis about links between the metabolisms of uric acid and
calcium. Both electrolytes are mainly reabsorbed in the proximal
tubule of the kidney. They are dependent on sodium reabsorption,
and on the renin-angiotensin-aldosterone system. The calcium
ATP-ase (PMCA) [37] and the sodium/calcium exchanger
(NCX1) [38] have been shown to be regulated by reactive oxygen
species and are also involved in calcium reabsorption by the
kidney [39]. Overall, the association of Cac with the NCCM risk
factor uric acid raises new hypothesis which should be explored
through new further studies.
GGT is an enzyme found mainly in the liver. It is involved in
glutathione metabolism, amino acid transfers, and leukotriene
metabolism [40]. An association between a progressive increase of
GGT activity and the number of the MSy components has
recently been reported [11].
GGT is also a marker of oxidative stress, even within its normal
range [41–45]. Apart from the typical serum GGT elevation due
to oxidative stress in the liver after alcohol consumption, GGT
could be an early marker of oxidative stress related to
atherosclerosis, diabetes and other cardiovascular disease.
In our study, uric acid, homocysteine and GGT were NCCM
risk factors most strongly associated with serum Cac. To the best of
our knowledge, this is the first time that associations of serum
calcium with uric acid, homocysteine or GGT are studied and
positive associations reported. Oxidative stress and calcium have
been extensively studied in the context of calcium transport and
signaling [46]. At the cellular level, oxidative stress causes calcium
influx into the cytoplasm, mitochondria, and nuclei. The
association between serum Cac and oxidative stress related factors
needs to be further explored. Of note, HDL-cholesterol, a
lipoprotein with anti-oxidant proprieties, was not significantly
associated with Cac. In a previous population-based study [5], Cac
was associated with HDL-cholesterol but only after excluding
individuals with mild primary hyperparathyroidism . Because
parathyroid hormone (PTH) was not available in our study we
cannot exclude a similar association.
We reported higher CRP levels in the upper Cac quintiles,
thought not significant. Higher CRP levels were associated with
higher calcium levels in chronic hemodialysis patients [47].
General population-based studies on the association of calcium
levels and CRP are lacking. The strong associations of Cac and
uric acid, homocysteine and GGT, and the lack of association with
CRP suggest that Cac is particularly related to oxidative stress
rather than to inflammation.
One should differentiate the issue of calcium intake and the one
of tightly regulated serum calcium levels. We found serum calcium
to be associated with a wide-range of metabolic disturbances. Our
findings provide no information on whether or not dietary calcium
intake plays a role in these metabolic disturbances.
Limitations
Our study has limitations. First, neither vitamin D nor PTH or
other new regulator of mineral metabolism (e.g., FGF-23, Klotho)
are available in our sample and we cannot explore whether the
association of serum calcium with these metabolic disturbances is
the result of, or mediated by, vitamin D or PTH action. Second,
we assigned the same weight to each cardio-metabolic risk factor
to derive the NCCM score. While we could have used unequal
weights, an equal weight approach has been privileged to be
concordant with the ATP III MSy criteria. Third, participants
included in the analysis differed by important characteristics from
the entire cohort, and thus our conclusions may not be
representative of the general Lausanne population. Finally, the
results from a cross-sectional study do not allow inferring causality.
While considering these limitations, our results confirmed
previous associations between serum calcium and MSy and
suggested that calcium metabolism could be considered as an
additional feature of the MSy. In addition, calcium metabolism
was associated with NCCM risk factors, including markers of
insulin resistance, independently of the conventional components
of the MSy and of BMI. The novel associations with oxidative
stress markers were the strongest and deserve further explorations.
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